VNDA — Vanda Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $244.87m
- $82.02m
- $216.11m
Brief: Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision To Uphold Approval Of Two Generic Versions Of Hetlioz
U.S. STOCKS ON THE MOVE-Soho House, Cogent Communications, Beyond
U.S. STOCKS ON THE MOVE-Soligenix, BioXcel, GoodRx
Brief: In A Major Win For Vanda, A Federal Appeals Court Overturns FDA's Order Denying Approval Of Hetlioz For The Treatment Of Jet Lag Disorder
U.S. STOCKS ON THE MOVE-CVS Health, TeraWulf, Yext
Vanda rises after federal court overturns FDA order denying drug approval
Vanda Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Vanda Pharmaceuticals Q2 revenue up 4%
Vanda Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S
Vanda Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Vanda Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: Drugmaker Vanda Announces Bysanti NDA Filing
Vanda Pharmaceuticals Inc expected to post a loss of 60 cents a share - Earnings Preview
Vanda Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Vanda Pharmaceuticals Q4 EPS USD -0.08
Vanda Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Vanda, Anaptys Bio Enter into Global Deal TO Develop & Market Imsidolimab
Vanda Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview